Evidence map›Paper›PMID 30143005›Full record

Trial reportBMC infectious diseases2018

Association of the Tyrosine/Nitrotyrosine pathway with death or ICU admission within 30 days for patients with community acquired pneumonia.

Thomas Baumgartner, Giedré Zurauskaité, Yannick Wirz, Marc Meier, Christian Steuer, Luca Bernasconi, Andreas Huber, Mirjam Christ-Crain, Christoph Henzen, Claus Hoess and 4 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 40% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Thomas BaumgartnerDivision of Endocrinology, Diabetology and Metabolism, Kantonsspital Aarau, Medical University Department, Aarau, Switzerland. baumth85@gmail.com.ORCID http://orcid.org/0000-0002-6782-0893
Giedré ZurauskaitéDivision of Endocrinology, Diabetology and Metabolism, Kantonsspital Aarau, Medical University Department, Aarau, Switzerland.
Yannick WirzDivision of Endocrinology, Diabetology and Metabolism, Kantonsspital Aarau, Medical University Department, Aarau, Switzerland.
Marc MeierDivision of Endocrinology, Diabetology and Metabolism, Kantonsspital Aarau, Medical University Department, Aarau, Switzerland.
Christian SteuerDepartment of Laboratory Medicine Kantonsspital Aarau, Aarau, Switzerland.
Luca BernasconiDepartment of Laboratory Medicine Kantonsspital Aarau, Aarau, Switzerland.
Andreas HuberDepartment of Laboratory Medicine Kantonsspital Aarau, Aarau, Switzerland.
Mirjam Christ-CrainEndocrinology, Diabetology and Metabolism, University Hospital Basel, Basel, Switzerland.
Christoph HenzenDepartment of Internal Medicine, Kantonsspital Luzern, Lucerne, Switzerland.
Claus HoessDepartment of Internal Medicine, Kantonsspital Münsterlingen, Münsterlingen, Switzerland.
Robert ThomannDepartment of Internal Medicine, Bürgerspital Solothurn, Solothurn, Switzerland.
Werner ZimmerliDepartment of Internal Medicine, Kantonsspital Liestal, Liestal, Switzerland.
Beat MuellerDivision of Endocrinology, Diabetology and Metabolism, Kantonsspital Aarau, Medical University Department, Aarau, Switzerland.
Philipp SchuetzDivision of Endocrinology, Diabetology and Metabolism, Kantonsspital Aarau, Medical University Department, Aarau, Switzerland.
Kantonsspital Aarau · CHKantonsspital Baselland · CHKantonsspital Münsterlingen · CHLuzerner Kantonsspital · CHSolothurner Spitäler · CHUniversity Hospital of Basel · CH

Funding

Forschungsrat Kantonsspital Aarau 1410.000.044Forschungsrat Kantonsspital Aarau 1410.000.058Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (CH) PP00P3_150531
6 · The paper itself

Abstract

backgroundOxidative stress is a modifiable risk-factor in infection causing damage to human cells. As an adaptive response, cells catabolize Tyrosine to 3-Nitrotyrosine (Tyr-NO2) by nitrosylation. We investigated whether a more efficient reduction in oxidative stress, mirrored by a lowering of Tyrosine, and an increase in Tyr-NO2 and the Tyrosine/Tyr-NO2 ratio was associated with better clinical outcomes in patients with community-acquired pneumonia (CAP).

methodsWe measured Tyrosine and Tyr-NO2 in CAP patients from a previous randomized Swiss multicenter trial. The primary endpoint was adverse outcome defined as death or ICU admission within 30-days; the secondary endpoint was 6-year mortality.

resultsOf 278 included CAP patients, 10.4% experienced an adverse outcome within 30 days and 45.0% died within 6 years. After adjusting for the pneumonia Severity Index [PSI], BMI and comorbidities, Tyrosine nitrosylation was associated with a lower risk for short-term adverse outcome and an adjusted OR of 0.44 (95% CI 0.20 to 0.96, p = 0.039) for Tyr-NO2 and 0.98 (95% CI 0.98 to 0.99, p = 0.043) for the Tyrosine/Tyr-NO2 ratio. There were no significant associations for long-term mortality over six-years for Tyr-NO2 levels (adjusted hazard ratio 0.81, 95% CI 0.60 to 1.11, p = 0.181) and Tyrosine/Tyr-NO2 ratio (adjusted hazard ratio 1.00, 95% CI 0.99 to 1.00, p = 0.216).

conclusionsTyrosine nitrosylation in our cohort was associated with better clinical outcomes of CAP patients at short-term, but not at long term. Whether therapeutic modulation of the Tyrosine/Tyr-NO2 pathway has beneficial effects should be evaluated in future studies.

trial registrationISRCTN95122877. Registered 31 July 2006.

Indexed as

AgedAged, 80 and overCohort StudiesCommunity-Acquired InfectionsFemaleFollow-Up StudiesHumansIntensive Care UnitsMaleMetabolic Networks and PathwaysMiddle AgedMortalityPatient AdmissionPneumoniaPrognosisRisk Factors3-nitrotyrosineTyrosine

Identifiers

PMID30143005
PMCPMC6109359
OpenAlexW2888381032

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.